Contact Us

• webcasts

TEXT SIZE

print share |

12.07.10   Webcasts from the American Society of Hematology Annual Meeting in 2010 about VELCADE Clinical Trials

---

06.08.10   2010 ASCO Annual Meeting VELCADE Webcasts

---

01.04.08   Dr. Harousseau - VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial
	Jean Luc Harousseau, MD Hematologie Clinique CHU Hotel Dieu Nantes, France Member, IMF Board of Scientific Advisors

---

01.04.08   Dr. Reeder - Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls
	Craig B. Reeder, MD Mayo Clinic Scottsdale, Arizona

---

01.02.08   Dr. Davies - The Combination of Velcade, Idarubicin and Melphalan (VIM) Demonstrates Significant Clinical Activity in Relapsed/Refractory Myeloma Patients
	Faith E. Davies, MD The Royal Marsden NHS Foundation Trust Sutton, Surrey, UK Member, IMF Board of Scientific Advisors

---

12.25.07   Dr. Jagannath - Updated Survival Analyses after Prolonged Follow-Up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma
	Sundar Jagannath, MD St. Vincent's Comprehensive Cancer Center New York, NY Member, IMF Board of Scientific Advisors

---

12.23.07   Dr. Bladé - The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure
	Joan Bladé, MD Hospital Clinic Hematology Barcelona, Spain Member, IMF Board of Scientific Advisors

---

12.23.07   Dr. Palumbo - Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m in Elderly Newly Diagnosed Patients: An Interim Analysis
	Antonio Palumbo, MD Ospedale Molinette Torino, Italy Member,IMF Board of Scientific Advisors

---

12.22.07   Dr. Jagannath - A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma
	Sundar Jagannath, MD St. Vincent's Comprehensive Cancer Center New York, New York Member, IMF Board of Scientific Advisors

---

12.20.07   Dr. San Miguel - A Phase 3 Study Comparing BortezomibMelphalanPrednisone (VMP) with MelphalanPrednisone (MP) in Newly Diagnosed Multiple Myeloma.
	Dr. Jesús San Miguel Hospital Clinico Universitario Universidad de Salamanca Salamanca, Spain Member, IMF Board of Scientific Advisors

---